Stock Track | Apnimed Soars 37.5% in Intraday Debut After Upsized IPO Priced at Top of Range

Stock Track

Jul 31

Shares of Apnimed (APMD) surged 37.5% in intraday trading on Friday, as the clinical-stage biotech made a strong debut on the Nasdaq Global Select Market. The stock opened significantly higher than its initial public offering price, reflecting robust investor appetite for the sleep apnea drug developer.

The rally was fueled by the company's upsized IPO, which priced 12 million shares at $16 apiece—the top of the marketed range of $14 to $16—raising $192 million. The deal was increased from an originally planned 10 million shares. Apnimed's sole clinical candidate, AD109 (Oxnimbi), is a once-daily oral treatment for obstructive sleep apnea, a condition with a large unmet medical need. The strong demand and premium pricing underscored confidence in the drug's potential.

The IPO was led by BofA, Evercore, Cantor Fitzgerald, and LifeSci Capital, with major shareholders including Morningside, Alpha Wave Ventures, and Japan's Shionogi & Co. The successful listing signals enthusiasm for biotech innovation in the sleep disorder space.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1184287020"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184287020\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184287020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184287020","market":"us","top_or_hot":-1,"title":"Stock Track | Apnimed Soars 37.5% in Intraday Debut After Upsized IPO Priced at Top of Range","media":"Stock Track","content":"<p>Shares of Apnimed (APMD) surged 37.5% in intraday trading on Friday, as the clinical-stage biotech made a strong debut on the Nasdaq Global Select Market. The stock opened significantly higher than its initial public offering price, reflecting robust investor appetite for the sleep apnea drug developer.</p><p>The rally was fueled by the company's upsized IPO, which priced 12 million shares at $16 apiece—the top of the marketed range of $14 to $16—raising $192 million. The deal was increased from an originally planned 10 million shares. Apnimed's sole clinical candidate, AD109 (Oxnimbi), is a once-daily oral treatment for obstructive sleep apnea, a condition with a large unmet medical need. The strong demand and premium pricing underscored confidence in the drug's potential.</p><p>The IPO was led by BofA, Evercore, Cantor Fitzgerald, and LifeSci Capital, with major shareholders including Morningside, Alpha Wave Ventures, and Japan's Shionogi & Co. The successful listing signals enthusiasm for biotech innovation in the sleep disorder space.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Apnimed Soars 37.5% in Intraday Debut After Upsized IPO Priced at Top of Range</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Apnimed Soars 37.5% in Intraday Debut After Upsized IPO Priced at Top of Range\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-31 23:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Apnimed (APMD) surged 37.5% in intraday trading on Friday, as the clinical-stage biotech made a strong debut on the Nasdaq Global Select Market. The stock opened significantly higher than its initial public offering price, reflecting robust investor appetite for the sleep apnea drug developer.</p><p>The rally was fueled by the company's upsized IPO, which priced 12 million shares at $16 apiece—the top of the marketed range of $14 to $16—raising $192 million. The deal was increased from an originally planned 10 million shares. Apnimed's sole clinical candidate, AD109 (Oxnimbi), is a once-daily oral treatment for obstructive sleep apnea, a condition with a large unmet medical need. The strong demand and premium pricing underscored confidence in the drug's potential.</p><p>The IPO was led by BofA, Evercore, Cantor Fitzgerald, and LifeSci Capital, with major shareholders including Morningside, Alpha Wave Ventures, and Japan's Shionogi & Co. The successful listing signals enthusiasm for biotech innovation in the sleep disorder space.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APMD","symbol_name":"Apnimed","start_time":0,"source_url":"","article_id":"1184287020","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184287020","pubTimestamp":1785512783,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Apnimed (APMD) surged 37.5% in intraday trading on Friday, as the clinical-stage biotech made a strong debut on the Nasdaq Global Select Market. The stock opened significantly higher than...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APMD":"Apnimed"},"translate_title":"股票跟踪 | Apnimed 首次公开募股 (IPO) 定价高于区间，盘中首日飙升 37.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APMD":1},"content_text":"Shares of Apnimed (APMD) surged 37.5% in intraday trading on Friday, as the clinical-stage biotech made a strong debut on the Nasdaq Global Select Market. The stock opened significantly higher than its initial public offering price, reflecting robust investor appetite for the sleep apnea drug developer.The rally was fueled by the company's upsized IPO, which priced 12 million shares at $16 apiece—the top of the marketed range of $14 to $16—raising $192 million. The deal was increased from an originally planned 10 million shares. Apnimed's sole clinical candidate, AD109 (Oxnimbi), is a once-daily oral treatment for obstructive sleep apnea, a condition with a large unmet medical need. The strong demand and premium pricing underscored confidence in the drug's potential.The IPO was led by BofA, Evercore, Cantor Fitzgerald, and LifeSci Capital, with major shareholders including Morningside, Alpha Wave Ventures, and Japan's Shionogi & Co. The successful listing signals enthusiasm for biotech innovation in the sleep disorder space.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}